Succinate Dehydrogenase (Fumarate Reductase)

A flavoprotein containing oxidoreductase that catalyzes the dehdyrogenation of SUCCINATE to fumerate. In most eukaryotic organisms this enzyme is a component of mitochondrial electron transport complex II.

Also Known As:

Networked: 1185 relevant articles (10 outcomes, 75 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pacak, Karel: 39 articles (12/2015 - 06/2005)
2.	Gimenez-Roqueplo, Anne-Paule: 22 articles (06/2015 - 09/2003)
3.	Bayley, Jean-Pierre: 18 articles (12/2015 - 01/2005)
4.	Eisenhofer, Graeme: 16 articles (06/2015 - 08/2005)
5.	Stratakis, Constantine A: 14 articles (02/2016 - 04/2008)
6.	de Krijger, Ronald R: 13 articles (10/2015 - 07/2002)
7.	Favier, Judith: 13 articles (06/2015 - 09/2003)
8.	Benn, Diana E: 13 articles (12/2014 - 03/2003)
9.	Devilee, Peter: 12 articles (11/2015 - 05/2004)
10.	Eng, Charis: 12 articles (05/2015 - 05/2002)

Related Diseases

1.	Huntington Disease (Huntington's Disease) 02/01/2001 - "A marked decrease in the activity of mitochondrial complex II (succinate dehydrogenase, SD) has been found in the brains of Huntington's disease (HD) patients. " 01/01/2015 - "There exists no therapeutic agent to address the disease.3-Nitropropionic acid (3-NP) which is a suicide inhibitor of succinate dehydrogenase and a well-known experimental model to study Huntington's disease, causes substantial impairment in gait and memory through oxidative and neuronal damage. " 04/04/2008 - "In the present study, 3 nitroproprionic acid (3NP), an irreversible inhibitor of succinate dehydrogenase (SD, complex II) has been employed to provide an experimental model of Huntington's disease (HD). " 04/16/2009 - "The alteration of succinate dehydrogenase activity has been linked to Huntington's disease. " 12/19/2003 - "Huntington's disease (HD) is associated with decreased activity of mitochondrial succinate dehydrogenase (complex II). "
2.	Paraganglioma (Paragangliomas) 05/01/2013 - "The aim of the present study was to review treatment results in patients with paraganglioma (PGL) of the neck presenting as carotid body tumour, long-term follow-up and relevance of genetic testing for succinate dehydrogenase (SDH)-gene mutations. " 05/01/2013 - "Germline mutations in succinate dehydrogenase (SDH) genes predispose carriers for developing paragangliomas, and studies on their quality of life (QoL) are scarce. " 08/01/2011 - "The purpose of this study was to investigate the somatic mutations of human mitochondria succinate dehydrogenase subunit B (SDHB) in sporadic paragangliomas. " 06/01/2009 - "Several studies have shown that patients with succinate dehydrogenase subunit B (SDHB) mutations have a very high risk for developing malignant paragangliomas. " 01/01/2016 - "About 70% paragangliomas are sporadic, 30% are hereditary, having identifiable germline mutations of Succinate Dehydrogenase enzyme (SDH). "
3.	Pheochromocytoma 07/01/2014 - "We report the case of a 35-year-old patient operated for a pheochromocytoma who turned out to be a carrier of a novel SDHD (succinate dehydrogenase subunit D) missense mutation. " 01/01/2014 - "The presence of the succinate dehydrogenase complex subunit D (SDHD) mutation that causes the pheochromocytoma was confirmed but no mutations in the family members were found. " 12/01/2010 - "A novel mutation of the succinate dehydrogenase B gene in a Korean family with pheochromocytoma." 11/01/2007 - "We also illustrate the importance of genetic testing in all patients with pheochromocytoma in pregnancy, especially with the emergence of new predisposing genes (succinate dehydrogenase B and D) and the recognition that germline mutations in these and more established genes (VHL and RET) account for over a quarter of all apparently sporadic cases." 08/01/2006 - "Mutations in the genes encoding succinate dehydrogenase (SDH) have been associated with susceptibility to pheochromocytoma. "
4.	Fatigue 12/01/2005 - "The differences between fatigue development in SMFs and FMFs during continuous activity were associated with fibre-type specific mATPase and succinate dehydrogenase activity." 12/01/2005 - "Smaller sized fibres (tonic and type 3) expressed higher succinate dehydrogenase activity than larger sized fibres (type 1-2, 2), which is related to the fatigue resistance. " 10/01/1992 - "Succinate dehydrogenase activity was directly related to fatigue resistance and inversely related to tetanic tension across the units. " 02/01/1985 - "Fatigue indices and succinic dehydrogenase (SDH) activities were determined in the extensor digitorum longus (EDL) and soleus muscles of the hind limb and the extensor carpi radialis longus of the forelimb in control and dystrophic mice aged 4 to 26 weeks. " 06/01/1982 - "In addition, the posterior cricoarytenoid is less resistant to fatigue and demonstrates lower succinic dehydrogenase activity. "
5.	Sepsis (Septicemia) 09/01/2015 - "Accordingly, we postulate that temporal administration with anti-oxidants targeting the mitochondria and/or succinate dehydrogenase inhibitors could be beneficial in sepsis and SIRS patients. " 10/01/2014 - "We therefore assessed the applicability of using GAPDH as a reference gene for expression studies in sepsis compared to other housekeeping genes (succinate dehydrogenase complex subunit A (SDHA), hypoxanthine phosphoribosyltransferase (HPRT)-1). " 09/01/2015 - "Specifically, this is due to a biochemical mechanism within the mitochondria where the oxidation of succinate to fumarate by succinate dehydrogenase (complex II) is reversed in sepsis (hypoxia), leading to succinate accumulation. "

Related Drugs and Biologics

1.	Enzymes
2.	3-nitropropionic acid
3.	NADH Dehydrogenase
4.	Peroxidase (Myeloperoxidase)
5.	NAD (NADH)
6.	Succinic Acid (Succinate)
7.	Proteins (Proteins, Gene)
8.	Cytochromes c (Cytochrome c)
9.	Probucol (Lorelco)
10.	succinobucol (AGI 1067)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Transplants (Transplant)
3.	Lasers (Laser)
4.	Ligation
5.	Subcutaneous Injections